![]() Today's news represents the third HuCAL-derived antibody to achieve this stage during the course of the year. The output of our partners' application of MorphoSys's proprietary HuCAL technology is becoming an increasingly visible and important value driver for our company." "Today's news underlines how important our core technology is to the pharmaceutical industry's drug pipeline," said Dr Simon Moroney, ceo of MorphoSys AG "We now have clinical trials of HuCAL-based antibodies ongoing with four different pharmaceutical companies. In the present programme, the HuCAL-derived antibody-drug conjugate incorporates technology licensed to Bayer Schering Pharma from Seattle Genetics. ADCs comprise antibodies linked to cytotoxic drugs, and combine the targeting properties of the antibody with the cell-destroying effect of the conjugated drug. The antibody is the first fully human HuCAL-based ADC to enter clinical trials. The current programme is directed against the target molecule MN, also known as carbonic anhydrase or CA IX for short, a tumour-associated antigen expressed in many tumour types under hypoxic conditions. This achievement marks a significant milestone within the Bayer Schering Pharma alliance and triggers a payment to MorphoSys AG, whose HuCAL technology was used to generate the fully human antibodies. The company’s services are tailored to its customers’ needs and Bayer Business Services contributes to their success by offering top quality at competitive prices.Bayer Schering Pharma has filed all necessary documentation to initiate a Phase 1 clinical trial with a HuCAL-derived antibody-drug conjugate (ADC) in the therapeutic area of oncology. Bayer Business Services in India provides IT services to all the sub-groups. Bayer Business Services is Bayer Group’s competence center for IT-based services and is a global company. A large proportion of sales are generated by products occupying leading positions on the world market. Our products enhance well-being and quality of life by diagnosing, preventing and treating disease.īayer CropScience operates in three business segments: Crop Protection, BioScience and Environmental Science - offering an outstanding range of products and extensive service backup for modern, sustainable agriculture as well as for non-agricultural applications.īayer MaterialScience is one of the world's leading manufacturers of innovative, high-performance materials for applications in numerous areas of our daily life. The aim of Bayer HealthCare is to discover and manufacture innovative products that will improve human and animal health worldwide. These provide us with access to major global growth markets and are supported by our service companies.īayer HealthCare operates in three business areas – Pharmaceuticals, Diabetes Care and Animal Health. We are firmly aligned to our mission statement “Bayer: Science For A Better Life” and continue to optimize our portfolio, concentrating our activities in three high-potential, efficient subgroups with largely independent operations: HealthCare, CropScience and MaterialScience. At the same time we want to create value through innovation, growth and high earning power. Our products and services are designed to benefit people and improve their quality of life. Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |